Category - Developments

Developments

MindMed collaborators post positive Phase 2 data with LSD in MDD

Prof. Matthias Liechti and Dr. Felix Mueller, Mind Medicine’s (NASDAQ:MNMD) collaborators at University Hospital Basel and the University Hospital of Psychiatry, released positive topline data from a double-blind...

April 14, 2023

Developments

FDA clears Candesant’s Brella to reduce excessive underarm sweating

The FDA cleared closely-held Candesant Biomedical’s Brella, the first and only three-minute SweatControl Patch for the reduction of excessive underarm sweating in adults with primary axillary hyperhidrosis. Brella uses...

April 13, 2023

Developments

Tonix expedites fibromyalgia and chronic migraine programs

Tonix Pharmaceuticals (NASDAQ:TNXP) is eliminating the interim analyses in its registration-enabling, confirmatory Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia and its Phase 2 PREVENTION study of TNX-1900 for...

April 13, 2023

Developments

KOL urges offering Profound’s TULSA-PRO to prostate cancer patients as part of informed consent

Y. Mark Hong, M.D., a key opinion leader (KOL) and world recognized urologist, suggests that if physicians aren’t offering or at least talking to their prostate cancer patients about Profound Medical’s (NASDAQ:PROF;...

April 11, 2023

Developments

Cantor eyes next NASH readout for Hepion’s rencofilstat

Cantor Fitzgerald is eagerly awaiting data from Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2 ALTITUDE-NASH liver function trial with its cyclophilin inhibitor, rencofilstat, guided for the second quarter of 2023. “We...

April 11, 2023

Developments

OpSens completes enrollment in SavvyWire study in Europe

OpSens (TSX:OPS; OTCQX:OPSSF) completed enrollment in the SAFE–TAVI clinical study, which is studying left ventricular rapid pacing using SavvyWire in transcatheter aortic valve implantation (TAVI or TAVR) procedures...

April 11, 2023

Developments

Vistagen receives new European patent for AV-101

The European Patent Office granted Vistagen (NASDAQ:VTGN) a patent for AV-101, its oral NMDAR (N-methyl-D-aspartate receptor) glycine site antagonist, a potential new oral treatment alternative for multiple CNS...

April 6, 2023

Developments

Miromatrix, CareDx in pact for bioengineered organs in human transplant

Miromatrix Medical (NASDAQ:MIRO) and CareDx (NASDAQ:CDNA) entered an exclusive partnership aimed at advancing the next wave of innovation using fully transplantable human bioengineered organs. CareDx will develop an...

April 5, 2023

Developments

PharmaJet to present immune response DNA vaccine data

Closely-held PharmaJet will present results of a comprehensive review of published scientific literature comparing data associated with various DNA vaccine delivery methods at the World Vaccine Congress 2023 on April 5...

April 4, 2023

Developments

Eckert & Ziegler to supply POINT Biopharma with Actinium-225

A subsidiary of POINT Biopharma Global (NASDAQ:PNT) signed an agreement for the supply of Actinium-225 (non-carrier-added Ac-225) from Eckert & Ziegler Strahlen EUZ (ETR) of Germany for POINT’s pipeline of next...

April 4, 2023

Category - Developments

Subscribe